Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation 

Slides:



Advertisements
Similar presentations
Resection of ascending aortic aneurysm without use of an interposition aortic graft John S. Ikonomidis, MD, PhD, FRCS(C), Abe DeAnda, MD, D.Craig Miller,
Advertisements

Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis James L. Cox, MD, Niv Ad, MD, Keith Myers, BS,
Of mice and men and surgical transcatheter aortic valve insertion
Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Manuel J. Antunes, MD, PhD, DSc 
Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysms 
Hemodynamics and myocardial blood flow patterns after placement of a cardiac passive restraint device in a model of dilated cardiomyopathy  Jennifer A.
Gorav Ailawadi, MD, Christopher W. Moehle, BS, Hong Pei, MD, Sandra P
Jeffrey A. Jones, PhD, Juozas A. Zavadzkas, MD, Eileen I
Building a bioartificial heart: A 3-song saga
Ground glass opacity of the lung: The veil that needs lifting
Right internal thoracic artery or saphenous vein grafting
Centers for Disease Control “increased-risk” organ donor: Not so risky?  Francis D. Pagani, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery 
Elevated messenger RNA expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic.
Victor van Berkel, MD, PhD 
William M. DeCampli, MD, PhD 
Spatiotemporal expression and localization of matrix metalloproteinas-9 in a murine model of thoracic aortic aneurysm  Jeffrey A. Jones, PhD, John R.
How should we treat air leaks?
Scott A. Hittinger, MD, Tom P. Theruvath, MD, PhD, John S
Bicuspid aortic valve aortopathy: One size fits all?
Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms  Joseph D. Schmoker, MD,
The lord of the rings  Antonio Miceli, MD, PhD 
Gastric conduit revision after esophagectomy: The raising of Lazarus
The variability of the mitral valve anatomy and terminology
Innovation and science: The future of valve design
The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery  Vinay Badhwar, MD  The Journal of Thoracic and.
It's not “just a shunt” but sometimes it should be…
Fixing the supply problem
Military surgeons just want to have fun
A first start for lung transplantation?
Confusion still exists regarding postoperative delirium and its etiology after esophagectomy  Robert B. Cameron, MD  The Journal of Thoracic and Cardiovascular.
Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005  Scott D. Barnett, PhD,
Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD 
Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD 
Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD 
Sinus of Valsalva aneurysms: Stabilizing the repair destabilizing the aortic valve?  M. Sertaç Çiçek, MD, FACC  The Journal of Thoracic and Cardiovascular.
Replicating the success of mitral valve repair in the aortic valve
Instrumental variable methods in clinical research
A fate worse than death  Jennifer S. Lawton, MD 
Attachment disorder in thoracoabdominal surgery
Video-assisted resection for lung cancer results in fewer complications  Lunxu Liu, PhD, MD, FRCS  The Journal of Thoracic and Cardiovascular Surgery 
We are the company we keep: The importance of the tumor microenvironment  Sai Yendamuri, MD, FACS  The Journal of Thoracic and Cardiovascular Surgery 
Passing the torch The Journal of Thoracic and Cardiovascular Surgery
Patrick T. Roughneen, MD, Grant T. Fankhauser, MD, Abe DeAnda, MD 
The origins of open heart surgery at the University of Minnesota 1951 to 1956  Richard A. DeWall, MD  The Journal of Thoracic and Cardiovascular Surgery 
The Journal of Thoracic and Cardiovascular Surgery
Discussion The Journal of Thoracic and Cardiovascular Surgery
Tissue valve, nitinol stent, or storage solution
The future of cardiac surgery training: A survival guide
Ventricular assistant in restrictive cardiomyopathy: Making the right connection  Robert D.B. Jaquiss, MD  The Journal of Thoracic and Cardiovascular Surgery 
The continuing challenge of congenital heart disease in China
Between a rock and a hard place
Vinay Badhwar, MD, John S. Ikonomidis, MD, PhD, Jeffrey P. Jacobs, MD 
“The more things change…”: The challenges ahead
Toward a more rational approach in treating type B aortic dissection
Evaluating the best approach to treatment of aortic stenosis: The jury is still out  Glen B. Taksler, PhD  The Journal of Thoracic and Cardiovascular Surgery 
Managing conflicts of interest
First in line for robotic surgery: Would you want to know?
Ryan R. Davies, MD  The Journal of Thoracic and Cardiovascular Surgery 
Apples remain apples NO matter what
Preoperative PFTs: The answer is blowing in the wind
Perioperative renal function and thoracoabdominal aneurysm repair: Where do we go from here?  Leonard N. Girardi, MD  The Journal of Thoracic and Cardiovascular.
Prognostic significance of early aortic remodeling in acute uncomplicated type B aortic dissection and intramural hematoma: Tell us what to do  Jean Bachet,
Did you like Terminator 3 better than Terminator 2
Journal changes and initiatives
Descending thoracic and thoracoabdominal aortic aneurysms: “Busted”
Zone zero thoracic endovascular aortic repair is all about “location, location, location”  Kevin L. Greason, MD  The Journal of Thoracic and Cardiovascular.
Calpain inhibitors: The aspirin of the 21st century?
John S. Ikonomidis, MD, PhD, Charlotte R. Ivey, BS, Jason B
Deciding how much to pay for effective care
Presentation transcript:

Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation  John R. Barbour, MD, Robert E. Stroud, MS, Abigail S. Lowry, BS, Leslie L. Clark, MS, Allyson M. Leone, BS, Jeffery A. Jones, PhD, Francis G. Spinale, MD, PhD, John S. Ikonomidis, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery  Volume 132, Issue 4, Pages 788-795 (October 2006) DOI: 10.1016/j.jtcvs.2006.05.052 Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Change in aortic diameter between baseline and terminal values, as measured by means of video micrometry. There was no change in aortic size at 24 hours; however, all time points 72 hours and beyond demonstrated statistical increase in size from baseline. Aortic size reached its greatest value at 4 weeks after thoracic aortic aneurysm (TAA) operations. *P < .05 from control, #P < .05 from 24 hours, +P < .05 from 72 hours, ϕP < .05 from 1 week, ΨP < .05 from 2 weeks. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 788-795DOI: (10.1016/j.jtcvs.2006.05.052) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 A, The representative immunoblot demonstrates the 58-kd band characteristic of active matrix metalloproteinase (MMP) 8. MMP-8 showed early increased abundance, which peaked at 72 hours after the operation; however, MMP-8 levels were found to be near control values by 1 week and remained near control values at all other time points in this study. *P < .05 from control, +P < .05 from 72 hours. B, The representative immunoblot demonstrates the 45-kd band characteristic of active MMP-12. MMP-12 levels were increased early and increased from control values at 24 hours. After this initial spike, MMP-12 levels were decreased in abundance at 1 week and returned to normal at 2 weeks. *P < .05 from control, #P < .05 from 24 hours, +P < .05 from 72 hours, ϕP < .05 from 1 week, ΨP < .05 from 2 weeks. TAA, Thoracic aortic aneurysm. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 788-795DOI: (10.1016/j.jtcvs.2006.05.052) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 A, The representative immunoblot shows the 62-kd band of active matrix metalloproteinase (MMP) 2. MMP-2 levels increased from control values at 72 hours and peaked in abundance at 1 week after the operation. MMP-2 levels then decreased to near control values at 2 weeks and at all time points afterward. *P < .05 from control, +P < .05 from 72 hours, φP < .05 from 1 week. B, The representative immunoblot shown in this figure shows the 88-kd band of active MMP-9. MMP-9 levels were decreased at 1 week; however, levels returned to control values at 2 weeks. MMP-9 levels were maximally increased at 8 weeks, although this increase was not significant from control values. *P < .05 from control, #P < .05 from 24 hours, +P < .05 from 72 hours, ϕP < .05 from 1 week. TAA, Thoracic aortic aneurysm. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 788-795DOI: (10.1016/j.jtcvs.2006.05.052) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 A, The representative immunoblot shows the 22-kd band of tissue inhibitor of metalloproteinases (TIMP) 1. TIMP-1 levels were found to be maximally decreased at 1 week before returning to control values at 2 weeks and beyond. *P < .05 from control, #P < .05 from 24 hours, +P < .05 from 72 hours, φP < .05 from 1 week. B, The representative immunoblot shows the 28-kd band characteristic of TIMP-4. TIMP-4 levels were not changed from control values until 4 weeks, when levels were markedly increased from control values and remained increased at 8 weeks. *P < .05 from control, #P < .05 from 24 hours, +P < .05 from 72 hours, ϕP < .05 from 1 week, ΨP < .05 from 2 weeks. TAA, Thoracic aortic aneurysm. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 788-795DOI: (10.1016/j.jtcvs.2006.05.052) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions